drugset / Trial / NCT05664737

A Study to Determine the Efficacy and Safety of Luspatercept in Adult Participants and to Evaluate the Safety and Pharmacokinetics in and Adolescent Participants With Alpha (α)-Thalassemia

NCT05664737

Phase 2 Recruiting 189 enrolled Bristol-Myers Squibb
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of the study is to evaluate the efficacy and safety of luspatercept plus best supportive care (BSC) vs placebo plus BSC on anemia in adult participants with α-thalassemia hemoglobin H (HbH) disease and determine the safety and drug levels in adolescent participants.

Timeline

Start
2022-12-09
Primary completion
2027-07-16
Completion
2034-08-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Luspatercept Protein / enzyme biologic

Indications